Protagonist Therapeutics (PTGX) The Citizens Life Sciences Conference 2026 summary

Strategic focus and differentiation

• Emphasis on peptide therapeutics, with expertise developed since 2008, leading to pioneering status in the field.

• Focus on addressing significant unmet needs with strong product differentiation, particularly through oral peptide solutions in markets dominated by injectables.

• Not confined to a single therapeutic area, but current pipeline centers on hematology, immunology/inflammation (I&I), and anti-obesity.

• Partnerships with major pharma companies provide financial flexibility and independence to support ongoing R&D.

Late-stage assets and partnerships

• Two late-stage partnered assets, rusfertide and icotrokinra, are expected to receive regulatory decisions in the third quarter of the year.

• Rusfertide targets polycythemia vera, addressing uncontrolled hematocrit in a large patient population with a novel hepcidin mimetic approach.

• Opting out of co-commercialization for rusfertide results in a royalty structure of 14%-29%, with a weighted average of 21% for the first $1.5B in sales.

• Icotrokinra (iCoTIDE), partnered with J&J, is the first oral IL-23 antagonist, with phase III data in psoriasis showing strong efficacy and safety.

• Royalty terms for icotrokinra are 6%-10%, with a weighted average of 7.25% for the first $4B in sales, and combined sales milestones for both drugs total $1.2B.

Market opportunity and product potential

• Rusfertide's data has been described as practice-changing, with positive patient-reported outcomes and broad applicability across disease stages.

• Icotrokinra's oral formulation offers a significant advantage in chronic indications, with market research indicating high willingness among patients to switch from injectables.

• Safety profile for icotrokinra is described as placebo-like, with strong efficacy in psoriasis, psoriatic arthritis, and ulcerative colitis.

• At $10B in peak sales for icotrokinra, royalty revenue is projected at $900M.